Next 10 |
NEW YORK, NY / ACCESSWIRE / November 20, 2023 / Qrons Inc. (OTCQB:QRON) announced that Professor Shiri Navon-Venezia has agreed to join Qrons Scientific Advisory Board. Professor Venezia is Professor of Microbiology, Head of Bacterial Pathogens & Antibiotic Resistance Lab in Ariel University...
NEW YORK, NY / ACCESSWIRE / August 23, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updat...
NEW YORK, NY / ACCESSWIRE / August 14, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the filing on August 9, of a United States Provisio...
NEW YORK, NY / ACCESSWIRE / July 20, 2023 / Qrons Inc. (OTCQB:QRON) announced today the signing of a License Agreement Term Sheet effective July 17, 2023 with Professors Benjamin Sredni & Michael Albeck of Bar Ilan University in Israel for an exclusive world-wide, perpetual license of their ...
NEW YORK, NY / ACCESSWIRE / March 22, 2023 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform for the treatment of traumatic brain injuries (TBIs) and other nervous system pathologies, today ...
NEW YORK, NY / ACCESSWIRE / December 14, 2022 / Qrons Inc. (OTCQB:QRON) announced today that it formed a collaboration with scientists at one of the largest public research universities in Israel, by which Tellurium based compounds in combination with Qrons' QS200™ product candidate and o...
NEW YORK, NY / ACCESSWIRE / April 12, 2022 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company dedicated to developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies announced the filing on Ap...
NEW YORK, NY / ACCESSWIRE / March 28, 2022 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company dedicated to developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies announced that the SEC dec...
NEW YORK, NY / ACCESSWIRE / April 22, 2021 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies is proud to report that the United Stat...
NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies is proud to announce the launch of i...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, NY / ACCESSWIRE / November 20, 2023 / Qrons Inc. (OTCQB:QRON) announced that Professor Shiri Navon-Venezia has agreed to join Qrons Scientific Advisory Board. Professor Venezia is Professor of Microbiology, Head of Bacterial Pathogens & Antibiotic Resistance Lab in Ariel University...
NEW YORK, NY / ACCESSWIRE / August 23, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products treatments and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the launch of its updat...
NEW YORK, NY / ACCESSWIRE / August 14, 2023 / Qrons Inc. (OTCQB:QRON) an innovative biotechnology company dedicated to developing products to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria, announced today the filing on August 9, of a United States Provisio...